Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors

Cancer Cell

Volumn 27, Issue 2, 2015, Pages 286-297

  Walz, Amy L ^a   Ooms, Ariadne ^b   Gadd, Samantha ^a   Gerhard, Daniela S ^c   Smith, Malcolm A ^c   GuidryAuvil, Jamie M ^c   Meerzaman, Daoud ^c   Chen, Qing Rong ^c   Hsu, ChihHao ^c   Yan, Chunhua ^c   Nguyen, Cu ^c   Hu, Ying ^c   Bowlby, Reanne ^d   Brooks, Denise ^d   Ma, Yussanne ^d   Mungall, Andrew J ^d   Moore, Richard A ^d   Schein, Jacqueline ^d   Marra, Marco A ^d,e   Huff, Vicki ^f   Dome, Jeffrey S ^g   Chi, Yueh Yun ^h   Mullighan, Charles G ⁱ   Ma, Jing ⁱ   Wheeler, David A ^j   Hampton, Oliver A ^j   Jafari, Nadereh ^k   Ross, Nicole ^l   Gastier Foster, Julie M ^l   Perlman, Elizabeth J ^a   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 200; NUCLEOTIDE; PROTEIN; PROTEIN DGCR8; PROTEIN DROSHA; PROTEIN LET 7A; SIX 1 2 HOMEODOMAIN PROTEIN; UNCLASSIFIED DRUG; DGCR8 PROTEIN, HUMAN; DROSHA PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MIRNLET7 MICRORNA, HUMAN; NERVE PROTEIN; RIBONUCLEASE III; RNA BINDING PROTEIN; SIX1 PROTEIN, HUMAN; SIX2 PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA SEQUENCE; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEPHROBLASTOMA; NONSENSE MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LOSS OF HETEROZYGOSITY; MICRORNAS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEASE III; RNA-BINDING PROTEINS; WILMS TUMOR;

EID: 84922778081     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.01.003     Document Type: Article

References (62)

1. Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., Marth G.T., McVean G.A. An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491:56-65. 1000 Genomes Project Consortium.
2. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7:248-249.
3. Bainbridge M.N., Hu H., Muzny D.M., Musante L., Lupski J.R., Graham B.H., Chen W., Gripp K.W., Jenny K., Wienker T.F., et al. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med 2013, 5:11.
4. Bardeesy N., Falkoff D., Petruzzi M.J., Nowak N., Zabel B., Adam M., Aguiar M.C., Grundy P., Shows T., Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 1994, 7:91-97.
5. Bartram M.P., Höhne M., Dafinger C., Völker L.A., Albersmeyer M., Heiss J., Göbel H., Brönneke H., Burst V., Liebau M.C., et al. Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT). J.Mol. Med. 2013, 91:739-748.
6. Beckwith J.B., Palmer N.F. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 1978, 41:1937-1948.
7. Beckwith J.B., Kiviat N.B., Bonadio J.F. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr. Pathol. 1990, 10:1-36.
8. Brunet J.P., Tamayo P., Golub T.R., Mesirov J.P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. U S A 2004, 101:4164-4169.
9. Carnevali P., Baccash J., Halpern A.L., Nazarenko I., Nilsen G.B., Pant K.P., Ebert J.C., Brownley A., Morenzoni M., Karpinchyk V., et al. Computational techniques for human genome resequencing using mated gapped reads. J.Comput. Biol. 2012, 19:279-292.
10. Ceppi P., Peter M.E. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 2014, 33:269-278.
11. Ceppi P., Mudduluru G., Kumarswamy R., Rapa I., Scagliotti G.V., Papotti M., Allgayer H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 2010, 8:1207-1216.
12. Chao L.Y., Huff V., Tomlinson G., Riccardi V.M., Strong L.C., Saunders G.F. Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat. Genet. 1993, 3:127-131.
13. Choi Y., Sims G.E., Murphy S., Miller J.R., Chan A.P. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 2012, 7:e46688.
14. Christensen K.L., Patrick A.N., McCoy E.L., Ford H.L. The six family of homeobox genes in development and cancer. Adv. Cancer Res. 2008, 101:93-126.
15. Cingolani P., Platts A., Wang L., Coon M., Nguyen T., Wang L., Land S.J., Lu X., Ruden D.M. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012, 6:80-92.
16. Cingolani P., Patel V.M., Coon M., Nguyen T., Land S.J., Ruden D.M., Lu X. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Genet. 2012, 3:35.
17. Dome J.S., Liu T., Krasin M., Lott L., Shearer P., Daw N.C., Billups C.A., Wilimas J.A. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J.Pediatr. Hematol. Oncol. 2002, 24:192-198.
18. Dome J.S., Fernandez C.V., Mullen E.A., Kalapurakal J.A., Geller J.I., Huff V., Gratias E.J., Dix D.B., Ehrlich P.F., Khanna G., et al. Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr. Blood Cancer 2013, 60:994-1000. COG Renal Tumors Committee.
19. Doros L.A., Rossi C.T., Yang J., Field A., Williams G.M., Messinger Y., Cajaiba M.M., Perlman E.J., A Schultz K., Cathro H.P., et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod. Pathol. 2014, 27:1267-1280.
20. Drmanac R., Sparks A.B., Callow M.J., Halpern A.L., Burns N.L., Kermani B.G., Carnevali P., Nazarenko I., Nilsen G.B., Yeung G., et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010, 327:78-81.
21. Edmonson M.N., Zhang J., Yan C., Finney R.P., Meerzaman D.M., Buetow K.H. Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011, 27:865-866.
22. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-D950.
23. Gadd S., Huff V., Huang C.C., Ruteshouser E.C., Dome J.S., Grundy P.E., Breslow N., Jennings L., Green D.M., Beckwith J.B., Perlman E.J. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia 2012, 14:742-756.
24. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60:167-179.
25. Gurtan A.M., Lu V., Bhutkar A., Sharp P.A. Invivo structure-function analysis of human Dicer reveals directional processing of precursor miRNAs. RNA 2012, 18:1116-1122.
26. Hill D.A., Ivanovich J., Priest J.R., Gurnett C.A., Dehner L.P., Desruisseau D., Jarzembowski J.A., Wikenheiser-Brokamp K.A., Suarez B.K., Whelan A.J., et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009, 325:965.
27. Ho J., Kreidberg J.A. MicroRNAs in renal development. Pediatr. Nephrol. 2013, 28:219-225.
28. Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., et al. SEER Cancer Statistics Review, 1975-2010 2013, National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2010/.
29. Hu Q., Gao F., Tian W., Ruteshouser E.C., Wang Y., Lazar A., Stewart J., Strong L.C., Behringer R.R., Huff V. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J.Clin. Invest. 2011, 121:174-183.
30. Hua Y., Larsen N., Kalyana-Sundaram S., Kjems J., Chinnaiyan A.M., Peter M.E. miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BCM Genom. 2013, 14:179. (http://www.biomedcentral.com/1471-2164/14/179).
31. Kelley L.A., Sternberg M.J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 2009, 4:363-371.
32. Kobayashi A., Valerius M.T., Mugford J.W., Carroll T.J., Self M., Oliver G., McMahon A.P. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 2008, 3:169-181.
33. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
34. Lambertz I., Nittner D., Mestdagh P., Denecker G., Vandesompele J., Dyer M.A., Marine J.C. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis invivo. Cell Death Differ. 2010, 17:633-641.
35. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
36. Li X., Oghi K.A., Zhang J., Krones A., Bush K.T., Glass C.K., Nigam S.K., Aggarwal A.K., Maas R., Rose D.W., Rosenfeld M.G. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 2003, 426:247-254.
37. Lupski J.R., Gonzaga-Jauregui C., Yang Y., Bainbridge M.N., Jhangiani S., Buhay C.J., Kovar C.L., Wang M., Hawes A.C., Reid J.G., et al. Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy. Genome Med. 2013, 5:57-70.
38. Maiti S., Alam R., Amos C.I., Huff V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000, 60:6288-6292.
39. McLaren W., Pritchard B., Rios D., Chen Y., Flicek P., Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010, 26:2069-2070.
40. Morin R., Bainbridge M., Fejes A., Hirst M., Krzywinski M., Pugh T., McDonald H., Varhol R., Jones S., Marra M. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 2008, 45:81-94.
41. Nicholson A.W. Ribonuclease III mechanisms of double-stranded RNA cleavage. Wiley Interdiscip. Rev. RNA 2014, 5:31-48.
42. Okada C., Yamashita E., Lee S.J., Shibata S., Katahira J., Nakagawa A., Yoneda Y., Tsukihara T. A high-resolution structure of the pre-microRNA nuclear export machinery. Science 2009, 326:1275-1279.
43. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors, ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
44. Patrick A.N., Schiemann B.J., Yang K., Zhao R., Ford H.L. Biochemical and functional characterization of six SIX1 branchio-oto-renal syndrome mutations. J.Biol. Chem. 2009, 284:20781-20790.
45. Pounds S., Cheng C., Mullighan C., Raimondi S.C., Shurtleff S., Downing J.R. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics 2009, 25:315-321.
46. Rakheja D., Chen K.S., Liu Y., Shukla A.A., Schmid V., Chang T.C., Khokhar S., Wickiser J.E., Karandikar N.J., Malter J.S., et al. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat. Commun. 2014, 2:4802.
47. Ravenel J.D., Broman K.W., Perlman E.J., Niemitz E.L., Jayawardena T.M., Bell D.W., Haber D.A., Uejima H., Feinberg A.P. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J.Natl. Cancer Inst. 2001, 93:1698-1703.
48. Rivera M.N., Haber D.A. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat. Rev. Cancer 2005, 5:699-712.
49. Ruteshouser E.C., Robinson S.M., Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008, 47:461-470.
50. Self M., Lagutin O.V., Bowling B., Hendrix J., Cai Y., Dressler G.R., Oliver G. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J. 2006, 25:5214-5228.
51. Senanayake U., Koller K., Pichler M., Leuschner I., Strohmaier H., Hadler U., Das S., Hoefler G., Guertl B. The pluripotent renal stem cell regulator SIX2 is activated in renal neoplasms and influences cellular proliferation and migration. Hum. Pathol. 2013, 44:336-345.
52. Sherry S.T., Ward M.H., Kholodov M., Baker J., Phan L., Smigielski E.M., Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29:308-311.
53. Slade I., Bacchelli C., Davies H., Murray A., Abbaszadeh F., Hanks S., Barfoot R., Burke A., Chisholm J., Hewitt M., et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J.Med. Genet. 2011, 48:273-278.
54. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A 2005, 102:15545-15550.
55. Torrezan G.T., Ferreira E.N., Nakahata A.M., Barros B.D., Castro M.T., Correa B.R., Krepischi A.C., Olivieri E.H., Cunha I.W., Tabori U., et al. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat. Commun. 2014, 5:4039.
56. Tusher V., Tibshirani R., Chu G. Significance analysis of microarrays applied to transcriptional responses to ionizing radiation. Proc. Natl. Acad. Sci. U S A 2001, 98:5116-5121.
57. Urbach A., Yermalovich A., Zhang J., Spina C.S., Zhu H., Perez-Atayde A.R., Shukrun R., Charlton J., Sebire N., Mifsud W., et al. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev. 2014, 28:971-982.
58. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.
59. Wegert J., Ishaque N., Vardapour R., Geörg C., Gu Z., Bieg M., Ziegler B., Bausenwein S., Nourkami N., Ludwig N., et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 2015, 27:298-311. this issue.
60. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11:228-234.
61. Wu M.K., Sabbaghian N., Xu B., Addidou-Kalucki S., Bernard C., Zou D., Reeve A.E., Eccles M.R., Cole C., Choong C.S., et al. Biallelic DICER1 mutations occur in Wilms tumours. J.Pathol. 2013, 230:154-164.
62. Xu P.X., Zheng W., Huang L., Maire P., Laclef C., Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development 2003, 130:3085-3094.